Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vertex reports positive safety results from hepatitis trial
“Chronic hepatitis C infection is a major public health problem, and Vertex's goal is to increase the success rate of hepatitis C treatment with short-duration therapy,” said Joshua
“Chronic hepatitis C infection is a major public health problem, and Vertex's goal is to increase the success rate of hepatitis C treatment with short-duration therapy,” said Joshua
The letter covers all formulations or drug combinations of phenylbutyrate being developed for the treatment of recurrent brain tumors. In addition to current worldwide rights, Somanta obtains a
PR-15 is being evaluated in a phase I single dose study which aims to define the safety, tolerability and PK/PD profile of the drug candidate. PR-15 is being
The Federal Trade Commission said it would not oppose the deal as long as the companies sell the drugs Zantac, Cortizone, Unisom and Balmex. Johnson & Johnson has
The modification to the business, which could transform the way drugs are delivered in the UK, will mean that only one or two logistics companies will distribute its
The first study evaluated the time to progression in newly-diagnosed multiple myeloma. The study compared the efficacy and safety of thalidomide plus dexamethasone compared to placebo plus dexamethasone.
The study demonstrated that rhesus monkeys injected with a synDNA HIV vaccine mounted a significant cellular immune response. The study involved monkeys treated with a synDNA vaccine targeting
Spectral’s shares nearly doubled and shot up by 95%. “We are confident that this assay will significantly improve Spectral’s growth opportunities,” stated Rob Verhagen, vice president of Business
Stroke patients are at an increased risk for developing blood clots known as venous thromboembolis (VTE). Without VTE prophylaxis, up to 75% of patients with hemiplegia following stroke
Enanta has discovered several hepatitis C virus protease inhibitors that have demonstrated attractive efficacy and pharmacokinetic profiles in preclinical studies. Under the terms of the agreement, Abbott gains